Compass Therapeutics Inc's Customers Performance

Name: Compass Therapeutics Inc Customers by Division and Industry - CSIMarket
Creator: CSIMarket.com
License: https://csimarket.com/help/terms-of-use

CMPX

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.


CMPX's Source of Revenues		• List of CMPX Customers

for the same period Compass Therapeutics Inc

• List of CMPX Customers

Select the Relationship:

Customers ▼

Select the Category:

Comparison ▼

Customers ▼

Basic Report▼

Compass Therapeutics Inc's Comment on Sales, Marketing and Customers

News about Compass Therapeutics Inc Contracts

Compass Therapeutics to Unveil CTX-471, a Groundbreaking CD137 Agonist Antibody, Demonstrating Anti-Tumor Activity in Patients Who Have Failed PD-1 or PD-L1 Inhibitors

Compass Therapeutics Presents Phase 1 Data for CTX-471, a Promising CD137 Agonist Antibody for Patients with Progressive Disease After PD-1/PD-L1 InhibitorsCompass Therapeutics, a clinical-stage biopharmaceutical company focused on developing antibody-based therapeutics for various diseases, has recently announced the upcoming presentation of their novel anti-CD137 agonist antibody, CTX-471. The presentation will take place at the American Society of Clinical Oncology (ASCO) Annual Meeting in 2024.CTX-471 has shown significant potential in the treatment of metastatic or locally advanced malignancies. Specifically, it has demonstrated anti-tumor activity in patients who have not responded adequately to approv...

Compass Therapeutics Displays Groundbreaking Therapeutic Solutions against Tumors at AACR 2024 Annual Meeting

At the annual meeting of the American Association for Cancer Research (AACR) held on April 9, 2024, in San Diego, California, Compass Therapeutics, Inc., a clinical-stage biopharmaceutical firm focused on oncology, showcased its advanced therapeutic data indicating the elimination of MHC Class I negative tumors in preclinical In Vivo models. Held at the San Diego Convention Center, the AACR s annual congregation marked a significant step in the journey towards innovative cancer treatments. Compass Therapeutics, traded on Nasdaq as CMPX, made a noteworthy contribution with its poster presentation on the anti-tumor activity of its bispecific antibody, CTX-009, and its agonistic anti-CD137 antibody, CTX-471.Kno...

CMPX's Stock Performance relative to it's Customers

CMPX's vs. Customers, Data

(Revenue and Income for Trailing 12 Months, in Millions of $, except Employees)

COMPANY NAME	MARKET CAP	REVENUES	INCOME	EMPLOYEES
Compass Therapeutics Inc	444.58	0.00	-68.17	39
SUBTOTAL	0.00	0.00	0.00	-

Sources: Compass Therapeutics Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Compass Therapeutics Inc’s corporate clients.
For your research, we’ve provided 9 tables on Compass Therapeutics Inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.